On December 31, 2024, Oncotelic Therapeutics, Inc. announced the launch of its artificial intelligence (AI) platform, PDAOAI, designed to streamline document search and analysis for knowledge-based industries, including pharmaceuticals and biotechnology. The platform, which has been under development for the past year, will be accessible through PDAO tokens, initially distributed to eligible shareholders in 2023.
PDAOAI transforms the way users navigate large document sets by enabling precise, parallel queries across structured datasets. The platform uses advanced semantic filtering and large language model (LLM)-based contextual answering, built on patent-pending technology. Unlike traditional AI chatbots, which often rely on broad search methods that may introduce bias and dilution, PDAOAI queries individual documents to provide precise, accurate answers from vast collections, including scientific articles and enterprise-level knowledge bases. This approach is scalable, supporting infinite documents and delivering fine-grained, precision-driven responses.
The platform is tailored for enterprise users and scientists, with an initial focus on the biotechnology industry. Sapu Bioscience, LLC, a subsidiary of GMP Biotechnology, Limited, in which Oncotelic holds a 45% stake, successfully utilized PDAOAI to train staff and implement standard operating procedures (SOPs) that enabled the facility to achieve GMP compliance in just one year. The platform accelerated employee development from entry level to high proficiency in record time.
Also Read: Cellipont & Xiogenix Partner to Boost Advanced Filling
PDAOAI will be governed by Oncotelic’s decentralized autonomous organization (DAO), Pet2DAO, through the PDAO token. This decentralized structure ensures transparent decision-making, community-driven governance, and eliminates the need for centralized authority in managing platform resources.
Oncotelic’s Product Manager, Scott Myers, expressed excitement about the success of PDAOAI at SAPU’s GMP facility, noting that the rapid onboarding into GMP is just the beginning. Mike Potts, VP of Data Science at Oncotelic, highlighted the game-changing impact of the combination of semantic filtering and contextual question-answering at the document level in improving document search, analysis, and summarization.
Saran Saund, Chief Business Officer at Oncotelic, emphasized that PDAOAI is already providing value for Sapu Biosciences, helping them advance beyond GMP compliance and accelerating drug development. He also mentioned the plans to expand the platform’s applications into sectors beyond life sciences, particularly semiconductors, where it holds the potential to drive significant innovation.